Diarrhea News and Research

Latest Diarrhea News and Research

GAVI to purchase $1 billion in childhood vaccines for distribution in 37 of the poorest nations

The Geneva-based GAVI Alliance, a fund backed by governments, the World Bank, the WHO and the Bill & Melinda Gates Foundation, said in an e-mailed statement on Tuesday that it will purchase more than $1 billion in vaccines against rotavirus, pneumococcal and other diseases through deals made with GlaxoSmithKline, Pfizer Inc. and Merck & Co. to immunize children in 37 of the poorest nations, Bloomberg reports.

28 Sep 2011

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta Pharmaceuticals Corp. announced that results of a Phase 1 study of ganetespib in combination with docetaxel in solid tumors were presented at the Annual Meeting of the European Society of Medical Oncology in Stockholm, Sweden.

27 Sep 2011

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

A research group led by Freiburg pharmacologist Prof. Dr. Klaus Aktories and their American colleagues have discovered the cell receptor for the toxin CDT of the bacterium Clostridium difficile.

27 Sep 2011

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech, a member of the Roche Group, today announced the results of the Phase II study TDM4450g in people with previously untreated HER2-positive metastatic breast cancer.

26 Sep 2011

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.

26 Sep 2011

Rotavirus vaccine saved 65,000 hospitalizations and $278 million in healthcare costs: Study

The latest research shows that since the 2006 introduction of routine inoculation against rotavirus -- a leading cause of diarrhea in infants and young children -- almost 65,000 fewer American children have been hospitalized and about $278 million in healthcare costs have been saved.

26 Sep 2011

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhea.

26 Sep 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

The U.S. Food and Drug Administration today approved Soliris (eculizumab) to treat patients with atypical Hemolytic Uremic Syndrome (aHUS), a rare and chronic blood disease that can lead to kidney (renal) failure and is also associated with increased risk of death and stroke.

26 Sep 2011

Is enough being done to fight child mortality?

Though the recent UNICEF report on child mortality shows progress is being made in every region to prevent childhood deaths, "it is clear that we still need to increase the coverage of high-impact, low-cost interventions like vaccines, including those for pneumonia and diarrhea that are rolling out," Melinda Gates, co-chair of the Bill & Melinda Gates Foundation.

23 Sep 2011

2M Pakistanis affected by diseases related to widespread flooding in southern region

Two million Pakistanis have become ill from malaria, diarrhea, skin diseases or snake bites "since monsoon rains left the southern region under several feet of water, the country's disaster authority said Thursday," Agence France-Presse reports. "More than 350 people have been killed and over eight million people have been affected this year by floods that officials say are worse in parts of Sindh province than last year," the news agency reports.

23 Sep 2011

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Astellas Pharma Europe Ltd. (APEL) and Optimer Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for DIFICLIR (fidaxomicin) tablets for the treatment of adults suffering with a Clostridium difficile infection (CDI), also known as C. difficile-associated diarrhoea (CDAD).

23 Sep 2011

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Amgen announced today that data from XGEVA (denosumab) and Vectibix (panitumumab) studies will be presented at the 2011 European Multidisciplinary Cancer Congress, Sept. 23 - 27, 2011, in Stockholm, Sweden.

23 Sep 2011

Vaccinating infants against rotavirus decreases health care use and treatment costs

Vaccinating infants against rotavirus has resulted in dramatic decreases in health care use and treatment costs for diarrhea-related illness in U.S. infants and young children, according to a new study by the Centers for Disease Control and Prevention. The study is published in the current issue of the New England Journal of Medicine.

22 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

According to new Dutch research featured in the September issue of The Journal of Nuclear Medicine, a peptide receptor radiolabeled therapy (PRRT), [177Lu-DOTA0,Tyr3]Octreotate (177Lu-octreotate), is effective not only in decreasing tumor size but also in reducing the severity of side effects that often accompany a cancer diagnosis.

22 Sep 2011

African Americans more likely than Caucasians to develop and die from lung cancer

Lung cancer, the leading cause of cancer death in the U.S., takes a particularly heavy toll on African Americans. Despite their lower smoking rates, African Americans are more likely than Caucasians to develop and die from lung cancer.

21 Sep 2011

UTHealth doctoral student receives ASM, NIH research fellowships for E. coli study

A doctoral student at The University of Texas Health Science Center at Houston (UTHealth) has been awarded two research fellowships to study the spread of E. coli, a hard-to-treat bacterium that can lead to food poisoning.

21 Sep 2011

ASU scientists receive USDA grants to combat food-related illness

Roughly 1 in six Americans are sickened every year by food-borne ailments, according to the Centers for Disease Control and Prevention. The effects of these illnesses range from acutely unpleasant to lethal, and the problem may be getting worse, as our food supply becomes more global, with an increasing number of antibiotic-resistant pathogens.

21 Sep 2011

Diarrhea News and Research

Latest Diarrhea News and Research

GAVI to purchase $1 billion in childhood vaccines for distribution in 37 of the poorest nations

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Researchers discover cell receptor for CDT toxin of C. difficile bacterium

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

Combination of Afinitor, exemestane reduces risk of breast cancer progression in women

Rotavirus vaccine saved 65,000 hospitalizations and $278 million in healthcare costs: Study

EMA CHMP adopts positive opinion for Optimer's DIFICLIR to treat C. difficile infection

Janssen Biotech receives FDA approval for Remicade to treat UC in children

Alexion receives FDA approval for Soliris to treat atypical Hemolytic Uremic Syndrome

Is enough being done to fight child mortality?

2M Pakistanis affected by diseases related to widespread flooding in southern region

EMA CHMP adopts positive opinion for DIFICLIR to treat C. difficile infection

Data from Amgen's XGEVA and Vectibix studies to be presented at EMCC 2011

Vaccinating infants against rotavirus decreases health care use and treatment costs

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Peptide receptor radiolabeled therapy shows promise against neuroendocrine tumors

African Americans more likely than Caucasians to develop and die from lung cancer

UTHealth doctoral student receives ASM, NIH research fellowships for E. coli study

ASU scientists receive USDA grants to combat food-related illness

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Diarrhea News and Research

Latest Diarrhea News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in